The clinical trial, sponsored by the University of Monastir, is investigating the efficacy of Atherolive, an olive leaf extract, in managing diabetes mellitus type 2. With an estimated enrollment of 500 patients, the study aims to establish the product's effectiveness in glycemic control compared to a placebo. Given the rising prevalence of diabetes globally, successful outcomes could position Atherolive as a viable alternative or adjunct to existing diabetes therapies, potentially capturing a significant share of the diabetes management market. The absence of exclusion criteria may facilitate broader patient recruitment, enhancing the trial's robustness. However, the competitive landscape includes established diabetes medications and emerging therapies, necessitating a strong differentiation strategy for Atherolive.